MAXHEALTH · NSE
Max Healthcare Institute Limited
₹1,049.3
+1.19% (+₹12.3)
Prev. close
₹1,037
Volume
20,98,416
Delivery %
64.9%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
3 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
1 · 0 bull / 0 neutral / 1 bear
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Max Healthcare Institute futures for the near-term, recommending a buy in the ₹1,020-1,040 range with targets…” | Jay ThakkarICICI Securities | Max Healthcare Institute | PENDING | |
| “Bullish on Max Healthcare Institute, recommending a buy at ₹1037 with a target of ₹1100 and a stop loss at ₹1015.” | Vaishali ParekhPrabhudas Lilladher | Max Healthcare Institute | PENDING | |
| “Bullish on Max Healthcare Institute futures, recommending a buy in the ₹995-1,000 range with a stop loss below ₹970 and …” | Jay ThakkarICICI Securities | Max Healthcare Institute | PENDING |
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Motilal Oswal reduced Max Healthcare's FY27 EPS estimate by 4% to ₹19.0 from ₹19.8, indicating a slightly tempered near-…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Max Healthcare | PENDING |
Fundamentals
About Max Healthcare Institute Limited
Max Healthcare Institute Limited provides medical and healthcare services in India. It offers services in various specialties, including cardiac sciences, orthopedics, oncology, renal sciences, neurosciences, minimal access and general surgery, pulmonology, obstetrics, bone marrow transplant, bariatric/weight loss surgery, gynecology, minimal access/laparoscopic surgery, eye care/ophthalmology, robotic surgery, paediatrics, nephrology, liver and biliary sciences, gastroenterology and GI surgery, internal medicine, organ transplants, and plastic and reconstructive surgery. The company also provides Max@Home, a platform that offers health and wellness services at home; and Max Lab, which provides diagnostic testing services to patients. In addition, it offers organ and tissue donation, preventive health checks, ambulance and immigration, air ambulance, and insurance and TPA services. The company provides healthcare services through a network of primary care clinics, multi-specialty hospitals/medical centres, and super-specialty hospital facilities. Max Healthcare Institute Limited was incorporated in 2001 and is based in Gurugram, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Colonel Harinder Singh Chehal
Headquarters
Gurugram
Website
maxhealthcare.inExchange
View on NSE ↗Key stats
Market cap
₹1.01 L Cr
P/E ratio (TTM)
69.8
Dividend yield
0.20%
EPS (TTM)
₹14.86
Beta (1Y · daily vs NIFTY 50)
0.69
Beta (5Y · monthly vs NIFTY 50)
0.85
Shares float
69.90 Cr
EPS · quarter ended Jun 2026
₹3.30
Upcoming earnings
20 Nov 2026
Financial Performance
01 · Financials
Revenue for Mar 2022–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2021 revenue as filed with BSE; the two sources' revenue definitions differ by 1.6% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,504.67 Cr | ₹3,931.46 Cr | ₹4,488.95 Cr | ₹5,309.48 Cr | ₹6,910.36 Cr | ₹8,225.43 Cr | |
| EBITDA | ₹518.60 Cr | ₹1,069.92 Cr | ₹1,367.23 Cr | ₹1,654.86 Cr | ₹1,914.54 Cr | ₹2,337.15 Cr |
| ₹-137.55 Cr | ₹605.05 Cr | ₹1,103.51 Cr | ₹1,057.64 Cr | ₹1,075.88 Cr | ₹1,442.41 Cr | |
| Diluted EPS | ₹-1.59 | ₹6.24 | ₹11.36 | ₹10.84 | ₹11.01 | ₹14.76 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹9,189.13 Cr | ₹10,101.85 Cr | ₹11,999.94 Cr | ₹15,214.48 Cr | ₹17,230.94 Cr | |
| — | ₹913.38 Cr | ₹688.96 Cr | ₹1,294.56 Cr | ₹3,010.29 Cr | ₹3,478.36 Cr | |
| Stockholders' equity | — | ₹6,282.47 Cr | ₹7,409.59 Cr | ₹8,408.14 Cr | ₹9,380.87 Cr | ₹10,746.63 Cr |
Total assets, Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| — | ₹117.86 Cr | ₹748.49 Cr | ₹1,284.13 Cr | ₹1,121.67 Cr | ₹1,437.96 Cr | ₹1,633.32 Cr | |
| Investing cash flow | — | ₹-73.00 Cr | ₹-771.77 Cr | ₹-102.32 Cr | ₹-1,285.45 Cr | ₹-1,610.69 Cr | ₹-1,688.99 Cr |
| ₹2,353.12 Cr | ₹191.33 Cr | ₹-294.17 Cr | ₹-288.56 Cr | ₹-263.74 Cr | ₹-163.16 Cr | ₹59.27 Cr | |
| Capital expenditure | — | ₹-118.42 Cr | ₹-561.31 Cr | ₹-335.61 Cr | ₹-785.95 Cr | ₹-944.48 Cr | ₹-1,484.53 Cr |
| End cash position | ₹111.01 Cr | ₹626.59 Cr | ₹309.14 Cr | ₹1,374.33 Cr | ₹979.71 Cr | ₹661.58 Cr | ₹665.80 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22–Jun 22(2Q) | Sep 22 | Dec 22 | Mar 23 | Jun 23–Sep 23(2Q) | Dec 23–Mar 24(2Q) | Jun 24–Sep 25(6Q) | Dec 25 | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 60.91% | 60.68% | 50.64% | 23.80% | 23.78% | 23.77% | 23.76% | 23.75% | 23.74% | 23.72% | 23.71% |
| Public | 39.09% | 39.32% | 49.36% | 76.20% | 76.22% | 76.23% | 76.24% | 76.25% | 76.26% | 76.28% | 76.29% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aurobindo Pharma Limited | ₹97,238.87 Cr | ₹1,734 | 26.4 | 2.57 | 9.2% | 0.21 | +6.4% | +53.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
22 indices
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.